Avalon GloboCare Advances AI-Enhanced Protein Design Technology for Cellular Therapy Development
09 Dicembre 2021 - 3:00PM
Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a
clinical-stage global developer of cell-based technologies and
therapeutics, today announced further advancement of the Company’s
sponsored research and licensing agreement with the Massachusetts
Institute of Technology (MIT). Avalon and MIT have combined their
artificial intelligence (AI)-enhanced protein design “QTY Code”
technology with Google’s AlphaFold2, a DeepMind AI program
developed to predict 3-dimensional (3D) protein structures of
previously difficult to work with drug targets. This new system is
designed to accelerate and advance Avalon’s capabilities in
developing novel targets for immuno-oncology and cellular medicine.
The “QTY Code” breakthrough technology, developed by Avalon and
the laboratory of Dr. Shuguang Zhang, Ph.D., of MIT’s Media lab in
Boston, MA, is a protein-design platform that can turn
water-insoluble transmembrane receptor proteins into water-soluble
proteins, enabling their use in many clinical applications,
including drug development. This program has already
successfully generated a series of decoy receptors, which function
to soak up excess chemokines and cytokines produced in the body
during a potentially fatal ‘cytokine storm.’ These cytokine storms
can occur in patients with COVID-19 and in cancer patients being
treated with CAR T-cell therapy.
The newly published study demonstrated the utility and
efficiency of combining the two AI-based technologies. The
researchers used the QTY code technology to design water-soluble
versions of chemokine receptors—water-insoluble proteins involved
in cytokine storms, cancer, autoimmune diseases and important drug
targets—and then used AlphaFold to accurately predict the
structures of these clinically important proteins.
Combining the “QTY code” with AlphaFold2, provides Avalon with a
novel, accurate, and efficient in-silico tool to improve knowledge
about important potential therapeutic targets such as transmembrane
receptors and other proteins to better understand their biology and
facilitate the development of novel cellular therapies.
“This new study with our collaborator, Dr. Shuguang Zhang from
MIT, has validated the innovative application of the QTY code
technology to transform important cellular therapy targets that
have been previously difficult to work with in the laboratory,”
said David Jin, M.D., Ph.D., President and Chief Executive Officer
of Avalon. “This new approach is advancing our capabilities in
designing novel immuno-oncology and cellular medicine therapies and
we are excited to continue to work with Dr. Zhang to advance these
drug development technologies,” added Dr. Jin.
The study of the new dual technology application was published
in the November 2021 issue of Life, an international,
peer-reviewed, open-access life sciences journal.
About Avalon GloboCare Corp.Avalon GloboCare
Corp. (NASDAQ: AVCO) is a clinical-stage, vertically integrated,
leading CellTech bio-developer dedicated to advancing and
empowering innovative, transformative immune effector cell therapy,
exosome technology, as well as COVID-19 related diagnostics and
therapeutics. Avalon also provides strategic advisory and
outsourcing services to facilitate and enhance its clients' growth
and development, as well as competitiveness in healthcare and
CellTech industry markets. Through its subsidiary structure with
unique integration of verticals from innovative R&D to
automated bioproduction and accelerated clinical development,
Avalon is establishing a leading role in the fields of cellular
immunotherapy (including CAR-T/NK), exosome technology (ACTEX™),
and regenerative therapeutics. For more information about Avalon
GloboCare, please visit www.avalon-globocare.com.
For the latest updates on Avalon GloboCare's developments,
please follow our twitter at @avalongc_avco
Forward-Looking StatementsCertain statements
contained in this press release may constitute "forward-looking
statements." Forward-looking statements provide current
expectations of future events based on certain assumptions and
include any statement that does not directly relate to any
historical or current fact. Actual results may differ materially
from those indicated by such forward-looking statements as a result
of various important factors as disclosed in our filings with the
Securities and Exchange Commission located at their website
(http://www.sec.gov). In addition to these factors, actual future
performance, outcomes, and results may differ materially because of
more general factors including (without limitation) general
industry and market conditions and growth rates, economic
conditions, and governmental and public policy changes. The
forward-looking statements included in this press release represent
the Company's views as of the date of this press release and these
views could change. However, while the Company may elect to update
these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing the Company's views as of any date subsequent to the
date of the press release.
Contact Information: Avalon GloboCare Corp.4400 Route 9, Suite
3100Freehold, NJ 07728PR@Avalon-GloboCare.com
Investor Relations:Crescendo Communications, LLCTel: (212)
671-1020 Ext. 304avco@crescendo-ir.com
Grafico Azioni Avalon GloboCare (NASDAQ:AVCO)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Avalon GloboCare (NASDAQ:AVCO)
Storico
Da Giu 2023 a Giu 2024